Portal de investigación
ESTUDIO ABIERTO MULTICÉNTRICO, DE ACCESO EXPANDIDO DE STI571, EN PACIENTES CON LEUCEMIA MIELOIDE CRÓNICA EN CRISIS BLÁSTICA LINFOIDE O MIELOIDE O CON LEUCEMIA MIELÓGENA AGUDA CROMOSOMA FILADELFIA POSITIVO.
Datos básicos
- Código:
- CSTI5710115
- Protocolo:
- CSTI5710115
- EUDRACT:
- NO PROCEDE
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
Oster, HS; (...); Mittelman, M
Article. 10.1182/bloodadvances.2020004055. 2021
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
Maggioni, Giulia; (...); Della Porta, Matteo G.
Article. 10.1016/S2352-3026(22)00323-4. 2023
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 10.1016/j.leukres.2023.107226. 2023
ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
Pfeilstoecker, M.; (...); Greenberg, P.
Meeting Abstract. 10.1016/j.leukres.2023.107230. 2023
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene (vol 12, 624, 2020)
Article. 10.3390/cancers13143440. 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
Dohner, H; (...); Ottmann, OG
Article. 10.1097/HS9.0000000000000617. 2021
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian; (...); Zeidan, Amer M.
Letter. 10.1182/bloodadvances.2022008747. 2023
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
Cerisoli, Francesco; (...); Hernandez Rivas, Jesus Maria
Article. 10.1016/j.jval.2022.04.1729. 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Madry, Krzysztof; (...); Smith, Alex
Article. 10.1111/bjh.18542. 2022
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; (...); Zeidan AM
Article. 10.1016/j.blre.2023.101128. 2023
Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2021-152678. 2021
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; (...); Della Porta MG
Article. 10.1200/JCO.23.02175. 2024
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
Riva, Elena; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-166050. 2022
CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS
Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel
Meeting Abstract. 2021
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 2021
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
Zeidan, Amer M.; (...); Fenaux, Pierre
Article. 10.1182/blood.2022018604. 2023
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Aakash, Fnu; (...); Loghavi, Sanam
Article. 10.1016/j.modpat.2024.100615. 2024
CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION
Hua, Chen-Liang Tzu; (...); Andres, Jerez
Meeting Abstract. 2021
Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre
Moreno, D; (...); Carpio, N
Meeting Abstract. 2021
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.
Article. 10.1016/j.blre.2023.101072. 2023
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.
Cicconi, L; (...); Abla, O
Article. 10.1038/s41408-021-00561-w. 2021
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Palanques-Pastor, Tomas; (...); Montesinos, Pau
Article. 10.1080/10428194.2021.1948031. 2021
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS; (...); Della Porta MG
Article. 10.1016/S2352-3026(24)00251-5. 2024
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I; (...); Siebert U
Article. 10.1182/bloodadvances.2022008360. 2023
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Santini, Valeria; (...); Zeidan, Amer M.
Meeting Abstract. 10.1182/blood-2022-160282. 2022
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.
Meeting Abstract. 10.1182/blood-2021-150766. 2021
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
Pfeilstocker, Michael; (...); Greenberg, Peter L.
Meeting Abstract. 10.1182/blood-2022-158671. 2022
Editorial introductions
Curigliano, Giuseppe; (...); Mateos, Maria-Victoria
Editorial Material. 10.1097/CCO.0000000000001001. 2023
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Enhancing roasted pepper quality sustainably: Impact of biodegradable mulches
Guerra, Marcos; (...); Casquero, Pedro Antonio
Article. 10.1016/j.jafr.2024.101393. 2024
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2022-168718. 2022
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia
Sossa, Claudia; (...); Marcela Cuervo, Diana
Meeting Abstract. 2023
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, Amer M.; (...); Santini, Valeria
Article. 10.1038/s41375-022-01724-9. 2022
GAM: General Auxetic Metamaterial with Tunable 3D Auxetic Behavior Using the Same Unit Cell Boundary Connectivity
Ben-Yelun, Ismael; (...); Saucedo-Mora, Luis
Article. 10.3390/ma16093473. 2023
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
D'Amico, Saverio; (...); Della Porta, Matteo Giovanni
Meeting Abstract. 10.1182/blood-2024-209541. 2024
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
Lin, Wei-Yu; (...); Allan, James M.
Article. 10.1038/s41467-021-27679-6. 2022
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Lin WY; (...); Allan JM
Article. 10.1038/s41467-021-26551-x. 2021
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E.; (...); Papaemmanuil, E.
Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023
Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.
Andres Regino, Carlos; (...); Angel Sanz, Miguel
Article. 10.1159/000528088. 2023
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
Roboz GJ; (...); Döhner H
Article. 10.1182/bloodadvances.2023012062. 2024
Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia.
Lozano ML, Sanz MA, Vicente V
Article. 10.1016/j.medcli.2021.03.017. 2021
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus
Meeting Abstract. 10.1182/blood-2021-149521. 2021
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
History of Acute Promyelocytic Leukemia.
Article. 10.2991/chi.k.210703.001. 2021
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.
Szabolcs, Paul; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.04.018. 2023
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
Matteuzzi, Tommaso; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-152215. 2021
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, Elsa; (...); Elias, Harold K
Article. 10.1038/s41591-021-01367-w. 2021
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; (...); Díaz TM
Article. 10.1002/cam4.6300. 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2022-162397. 2022
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact.
Garcia-Vidal C; (...); Soriano A
Article. 10.1007/s40121-024-00938-x. 2024
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.
Cruz, David; (...); Gallardo, David
Article. 10.3389/fimmu.2023.1066393. 2023
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gomez, E; (...); Fernandez-Rodriguez, C M
Article. 10.1111/apt.18004. 2024
Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
de Koning, Coco; (...); Nierkens, Stefan
Article. 10.1038/s41409-021-01417-4. 2021
LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167138. 2022
Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2023-183029. 2023
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F; (...); Pleyer L
Article. 10.1182/blood.2023023476. 2024
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
Bowen, David; (...); de Witte, Theo M.
Meeting Abstract. 10.1182/blood-2021-150322. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Smoljanovic, Inga Mandac; (...); Bowen, David
Meeting Abstract. 10.1182/blood-2022-167716. 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C; (...); Passamonti F
Article. 10.1016/j.esmoop.2022.100403. 2022
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko, Maria; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023723. 2024
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Rücker FG; (...); Doehner, Konstanze
Article. 10.1038/s41375-021-01323-0. 2021
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-186863. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Bernard, Elsa; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023727. 2024
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; (...); Tormo, M
Article. 10.1111/bjh.17675. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz, ME; (...); Sanz, G
Article. 10.1182/blood.2021011719. 2021
Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)
Kayser, Sabine; (...); Montesinos, Pau
Correction. 10.1038/s41375-021-01358-3. 2021
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero, Juan Carlos; (...); Diez Campelo, Maria
Article. 10.1177/20406207231218157. 2024
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY
Lang, K.; (...); Bullinger, L.
Meeting Abstract. 2023
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-157549. 2022
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-145002. 2021
PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY
Jorge, Labrador; (...); Miguel-Angel, Sanz
Meeting Abstract. 2021
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Roboz, Gail J.; (...); Wei, Andrew H.
Letter. 10.1080/10428194.2021.2012667. 2022
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem
Meeting Abstract. 2023
RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.; (...); Yacoub, A.
Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023
Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Saiz-Rodriguez, M; (...); Pethema Grp
Meeting Abstract. 2021
REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID
Jorge, Labrador; (...); Pau, Montesinos
Meeting Abstract. 2021
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
Sauta, Elisabetta; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-163634. 2022
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni
Article. 10.1200/JCO.22.01784. 2023
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernandez-Sanchez, Alberto; (...); Bullinger, Lars
Article. 10.1038/s41375-024-02333-4. 2024
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167480. 2022
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reply.
Lozano Almela, Maria Luisa, Sanz Alonso, Miguel Angel, Vicente Garcia, Vicente
Letter. 10.1016/j.medcli.2021.09.029. 2022
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*
Triguero, A.; (...); Sanz, G.
Article. 10.1016/j.leukres.2022.106836. 2022
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147769. 2021
Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.; (...); Garcia-Manero, Guillermo
Meeting Abstract. 10.1182/blood-2021-145626. 2021
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.
Zeidan AM; (...); Santini V
Article. 10.2217/fon-2022-1237. 2023
Summer Pruning, an Eco-Friendly Approach to Controlling Bitter Pit and Preserving Sensory Quality in Highly Vigorous Apple cv. 'Reinette du Canada'
Guerra, Marcos; (...); Antonio Casquero, Pedro
Article. 10.3390/agriculture11111081. 2021
Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia
Melo, CLS; (...); Montesinos, P
Meeting Abstract. 2021
Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia
Ortiz, MF; (...); Sossa, C
Meeting Abstract. 2021
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
Kanda, Junya; (...); Gluckman, Eliane
Article. 10.1038/s41409-021-01479-4. 2022
The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2021
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Article. 10.1038/s41409-024-02298-z. 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Efficace, Fabio; (...); Zeidan, Amer M
Article. 10.1002/hem3.69. 2024
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Diez-Campelo, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2021-146019. 2021
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-182949. 2023
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022